Chikungunya virus and prospects for a vaccine

Scott Weaver, Jorge E. Osorio, Jill A. Livengood, Rubing Chen, Dan T. Stinchcomb

Research output: Contribution to journalArticle

141 Citations (Scopus)

Abstract

In 2004, chikungunya virus (CHIKV) re-emerged from East Africa to cause devastating epidemics of debilitating and often chronic arthralgia that have affected millions of people in the Indian Ocean Basin and Asia. More limited epidemics initiated by travelers subsequently occurred in Italy and France, as well as human cases exported to most regions of the world, including the Americas where CHIKV could become endemic. Because CHIKV circulates during epidemics in an urban mosquito-human cycle, control of transmission relies on mosquito abatement, which is rarely effective. Furthermore, there is no antiviral treatment for CHIKV infection and no licensed vaccine to prevent disease. Here, we discuss the challenges to the development of a safe, effective and affordable chikungunya vaccine and recent progress toward this goal.

Original languageEnglish (US)
Pages (from-to)1087-1101
Number of pages15
JournalExpert Review of Vaccines
Volume11
Issue number9
DOIs
StatePublished - Sep 2012

Fingerprint

Chikungunya virus
Vaccines
Culicidae
Indian Ocean
Eastern Africa
Arthralgia
Italy
France
Antiviral Agents
Therapeutics

Keywords

  • alphavirus
  • antibody
  • chikungunya
  • emergence
  • evolution
  • mosquito
  • vaccine

ASJC Scopus subject areas

  • Immunology
  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

Weaver, S., Osorio, J. E., Livengood, J. A., Chen, R., & Stinchcomb, D. T. (2012). Chikungunya virus and prospects for a vaccine. Expert Review of Vaccines, 11(9), 1087-1101. https://doi.org/10.1586/erv.12.84

Chikungunya virus and prospects for a vaccine. / Weaver, Scott; Osorio, Jorge E.; Livengood, Jill A.; Chen, Rubing; Stinchcomb, Dan T.

In: Expert Review of Vaccines, Vol. 11, No. 9, 09.2012, p. 1087-1101.

Research output: Contribution to journalArticle

Weaver, S, Osorio, JE, Livengood, JA, Chen, R & Stinchcomb, DT 2012, 'Chikungunya virus and prospects for a vaccine', Expert Review of Vaccines, vol. 11, no. 9, pp. 1087-1101. https://doi.org/10.1586/erv.12.84
Weaver S, Osorio JE, Livengood JA, Chen R, Stinchcomb DT. Chikungunya virus and prospects for a vaccine. Expert Review of Vaccines. 2012 Sep;11(9):1087-1101. https://doi.org/10.1586/erv.12.84
Weaver, Scott ; Osorio, Jorge E. ; Livengood, Jill A. ; Chen, Rubing ; Stinchcomb, Dan T. / Chikungunya virus and prospects for a vaccine. In: Expert Review of Vaccines. 2012 ; Vol. 11, No. 9. pp. 1087-1101.
@article{91aa7c8913b1481c83fd30457e3046e8,
title = "Chikungunya virus and prospects for a vaccine",
abstract = "In 2004, chikungunya virus (CHIKV) re-emerged from East Africa to cause devastating epidemics of debilitating and often chronic arthralgia that have affected millions of people in the Indian Ocean Basin and Asia. More limited epidemics initiated by travelers subsequently occurred in Italy and France, as well as human cases exported to most regions of the world, including the Americas where CHIKV could become endemic. Because CHIKV circulates during epidemics in an urban mosquito-human cycle, control of transmission relies on mosquito abatement, which is rarely effective. Furthermore, there is no antiviral treatment for CHIKV infection and no licensed vaccine to prevent disease. Here, we discuss the challenges to the development of a safe, effective and affordable chikungunya vaccine and recent progress toward this goal.",
keywords = "alphavirus, antibody, chikungunya, emergence, evolution, mosquito, vaccine",
author = "Scott Weaver and Osorio, {Jorge E.} and Livengood, {Jill A.} and Rubing Chen and Stinchcomb, {Dan T.}",
year = "2012",
month = "9",
doi = "10.1586/erv.12.84",
language = "English (US)",
volume = "11",
pages = "1087--1101",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "9",

}

TY - JOUR

T1 - Chikungunya virus and prospects for a vaccine

AU - Weaver, Scott

AU - Osorio, Jorge E.

AU - Livengood, Jill A.

AU - Chen, Rubing

AU - Stinchcomb, Dan T.

PY - 2012/9

Y1 - 2012/9

N2 - In 2004, chikungunya virus (CHIKV) re-emerged from East Africa to cause devastating epidemics of debilitating and often chronic arthralgia that have affected millions of people in the Indian Ocean Basin and Asia. More limited epidemics initiated by travelers subsequently occurred in Italy and France, as well as human cases exported to most regions of the world, including the Americas where CHIKV could become endemic. Because CHIKV circulates during epidemics in an urban mosquito-human cycle, control of transmission relies on mosquito abatement, which is rarely effective. Furthermore, there is no antiviral treatment for CHIKV infection and no licensed vaccine to prevent disease. Here, we discuss the challenges to the development of a safe, effective and affordable chikungunya vaccine and recent progress toward this goal.

AB - In 2004, chikungunya virus (CHIKV) re-emerged from East Africa to cause devastating epidemics of debilitating and often chronic arthralgia that have affected millions of people in the Indian Ocean Basin and Asia. More limited epidemics initiated by travelers subsequently occurred in Italy and France, as well as human cases exported to most regions of the world, including the Americas where CHIKV could become endemic. Because CHIKV circulates during epidemics in an urban mosquito-human cycle, control of transmission relies on mosquito abatement, which is rarely effective. Furthermore, there is no antiviral treatment for CHIKV infection and no licensed vaccine to prevent disease. Here, we discuss the challenges to the development of a safe, effective and affordable chikungunya vaccine and recent progress toward this goal.

KW - alphavirus

KW - antibody

KW - chikungunya

KW - emergence

KW - evolution

KW - mosquito

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=84869454683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869454683&partnerID=8YFLogxK

U2 - 10.1586/erv.12.84

DO - 10.1586/erv.12.84

M3 - Article

VL - 11

SP - 1087

EP - 1101

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 9

ER -